• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低强度脐带血移植作为移植物失败挽救治疗的可行性:一项全国性成年患者调查结果。

Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

机构信息

Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Biol Blood Marrow Transplant. 2011 Jun;17(6):841-51. doi: 10.1016/j.bbmt.2010.09.005. Epub 2010 Sep 16.

DOI:10.1016/j.bbmt.2010.09.005
PMID:20849969
Abstract

To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after graft failure (GF), we surveyed the data of 80 adult patients (median age, 51 years) who received CBT within 3 months of GF (primary 64, secondary 16), with fludarabine-based reduced-intensity regimens with or without melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number of 2.4 × 10(7)/kg total nucleated cells (TNC) were infused, and among the 61 evaluable patients who survived for more than 28 days, 45 (74%) engrafted. The median follow-up of surviving patients was 325 days, and the 1-year overall survival rate was 33% despite poor performance status (2-4, 60%), carryover organ toxicities (grade 3/4, 14%), and infections (82%) prior to CBT. Day 100 transplantation-related mortality was 45%, with 60% related to infectious complications. Multivariate analysis showed that the infusion of TNC ≥2.5 × 10(7)/kg and an alkylating agent-containing regimen were associated with a higher probability of engraftment, and that high risk-status at the preceding transplantation and grade 3/4 organ toxicities before CBT were associated with an increased risk of mortality. In conclusion, in an older population of patients, our data support the feasibility of CBT with a reduced-intensity conditioning regimen for GF.

摘要

为了评估脐带血移植(CBT)是否可以改善移植物衰竭(GF)后的不良生存情况,我们调查了 80 例成人患者(中位年龄,51 岁)的数据,这些患者在 GF 后 3 个月内接受了 CBT(原发性 64 例,继发性 16 例),采用基于氟达拉滨的低强度方案,联合或不联合马法兰、白消安、环磷酰胺和/或 2-4Gy 全身照射(TBI)。输注的中位数为 2.4×10(7)/kg 总核细胞(TNC),在 61 例可评估的存活超过 28 天的患者中,有 45 例(74%)植活。存活患者的中位随访时间为 325 天,尽管患者的表现状态较差(2-4 级,60%)、移植物抗宿主病(GVHD)毒性持续存在(3/4 级,14%)和感染(82%)在前,1 年总生存率仍为 33%。移植后第 100 天的移植相关死亡率为 45%,其中 60%与感染并发症有关。多变量分析显示,输注 TNC≥2.5×10(7)/kg 和含有烷化剂的方案与更高的植活概率相关,而在前一次移植时的高危状态和 CBT 前 3/4 级器官毒性与死亡率增加相关。总之,在年龄较大的患者群体中,我们的数据支持采用低强度预处理方案进行 CBT 治疗 GF 的可行性。

相似文献

1
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.降低强度脐带血移植作为移植物失败挽救治疗的可行性:一项全国性成年患者调查结果。
Biol Blood Marrow Transplant. 2011 Jun;17(6):841-51. doi: 10.1016/j.bbmt.2010.09.005. Epub 2010 Sep 16.
2
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.使用氟达拉滨和白消安的低强度预处理方案后,不匹配无关脐血移植成功植入。
Ann Hematol. 2007 Jan;86(1):49-54. doi: 10.1007/s00277-006-0190-5. Epub 2006 Oct 12.
3
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.对于骨髓增生异常综合征患者,采用基于氟达拉滨的剂量降低预处理方案,随后接受来自相关或无关供体的异基因干细胞移植。
Bone Marrow Transplant. 2001 Oct;28(7):643-7. doi: 10.1038/sj.bmt.1703215.
4
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.白消安/美法仑/抗胸腺细胞球蛋白联合非血缘供者脐血移植治疗婴儿白血病和幼儿白血病:脐血移植研究(COBLT)经验
Biol Blood Marrow Transplant. 2005 Aug;11(8):637-46. doi: 10.1016/j.bbmt.2005.05.003.
5
Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.氟达拉滨为基础的预处理化疗用于获得性重型再生障碍性贫血的异基因造血干细胞移植。
Biol Blood Marrow Transplant. 2011 May;17(5):717-22. doi: 10.1016/j.bbmt.2010.08.013. Epub 2010 Aug 22.
6
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.采用基于氟达拉滨的低强度预处理方案进行异基因外周血干细胞移植治疗恶性淋巴瘤。
Bone Marrow Transplant. 2000 May;25(10):1021-8. doi: 10.1038/sj.bmt.1702392.
7
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.氟达拉滨/美法仑预处理用于多发性骨髓瘤患者的异基因移植
Bone Marrow Transplant. 2002 Sep;30(6):367-73. doi: 10.1038/sj.bmt.1703652.
8
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.在患有骨髓增生异常综合征或继发性急性髓系白血病的患者中,基于氟达拉滨/白消安的减低强度预处理后进行异基因干细胞移植。
Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1.
9
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.使用外周血干细胞和基于氟达拉滨的预处理方案对重症难治性再生障碍性贫血患者进行同种异体移植:墨西哥的经验。
Am J Hematol. 2006 Mar;81(3):157-61. doi: 10.1002/ajh.20467.
10
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.采用静脉注射白消安、氟达拉滨和兔抗胸腺细胞球蛋白对患有非恶性疾病和慢性粒细胞白血病的儿童进行减低强度预处理。
Bone Marrow Transplant. 2006 Feb;37(3):263-9. doi: 10.1038/sj.bmt.1705240.

引用本文的文献

1
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience.第二次异基因干细胞移植治疗移植物失败或移植物功能不良后的结局:单中心经验
Stem Cell Rev Rep. 2025 Jun 5. doi: 10.1007/s12015-025-10903-x.
2
Second Allogeneic Hematopoietic Cell Transplantation Following Graft Failure in Children.儿童移植物失败后的第二次异基因造血细胞移植
J Korean Med Sci. 2025 Mar 17;40(10):e48. doi: 10.3346/jkms.2025.40.e48.
3
Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?
急性白血病患儿异基因造血干细胞移植后的移植物失败:自体重建还是二次移植?
Stem Cell Res Ther. 2024 Apr 22;15(1):111. doi: 10.1186/s13287-024-03726-z.
4
Kinetics of neutrophil engraftment in allogeneic stem cell transplantation.异基因干细胞移植中中性粒细胞植入的动力学
Blood Cell Ther. 2019 Apr 1;2(2):22-30. doi: 10.31547/bct-2018-011. eCollection 2019 May 10.
5
Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years.成人急性髓系白血病初次异基因移植后挽救性单单位非血缘脐血移植治疗移植失败:过去20年的结局趋势
Bone Marrow Transplant. 2022 Dec;57(12):1848-1850. doi: 10.1038/s41409-022-01840-1. Epub 2022 Oct 4.
6
Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure.挽救性脐带血移植采用短期减低强度预处理方案治疗移植物失败。
Intern Med. 2022 Jun 1;61(11):1673-1679. doi: 10.2169/internalmedicine.7836-21. Epub 2021 Nov 20.
7
Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后移植物失败行单倍体相合和脐血挽救性移植的结局比较。
Bone Marrow Transplant. 2020 Sep;55(9):1784-1795. doi: 10.1038/s41409-020-0821-9. Epub 2020 Feb 12.
8
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.采用氟达拉滨、美法仑和低剂量抗胸腺细胞球蛋白预处理方案进行挽救性脐血移植的可行性。
Int J Hematol. 2019 Apr;109(4):463-469. doi: 10.1007/s12185-019-02610-4. Epub 2019 Feb 8.
9
Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.氟达拉滨、美法仑和低剂量全身照射后进行挽救性脐血移植治疗造血干细胞移植后移植物排斥反应的可行性
Bone Marrow Transplant. 2016 Jul;51(7):985-7. doi: 10.1038/bmt.2016.16. Epub 2016 Feb 15.
10
Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.用于移植物失败的第二次异基因造血细胞移植:中性粒细胞减少性移植物失败的预后较差。
Am J Hematol. 2015 Oct;90(10):892-6. doi: 10.1002/ajh.24111.